Roche, GlaxoSmithKline: Study shows women more likely to stay on Boniva for osteoporosis

By E. Janene Geiss

Philadelphia, Sept. 18 - Hoffmann-La Roche, Inc. and GlaxoSmithKline said Sunday that six-month results of ongoing studies show that women with postmenopausal osteoporosis taking once-monthly Boniva (ibandronate sodium) were about 25% more likely to stay on therapy than women taking the once-weekly medications, alendronate or risedronate.

To ensure the results reflect the independent effect of once-monthly dosing with Boniva, the analyses controlled for factors that could affect persistence with therapy, including age, other medical conditions and out-of-pocket costs for the medications, according to a joint news release from Nutley, N.J.-based Roche and London-based GlaxoSmithKline.

These findings were presented Sunday at the annual meeting of the American Society for Bone and Mineral Research. Previous studies show that staying on daily or weekly bisphosphonate therapy may result in fewer fractures and reduced health care costs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.